Entacapone: adjunctive use in patients with advanced Parkinson's disease.
McAuley
L
L
Canadian Coordinating Office for Health Technology Assessment.
D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use; D002170:Canada; D002396:Catechols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000191:economics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics; D013673:Technology Assessment, Biomedical
D000978:Antiparkinson Agents; D002396:Catechols; D004791:Enzyme Inhibitors; D007980:Levodopa